ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Lowering Meld, Diminishing Length of Stay, and Increasing Liver Transplant Numbers Comes Through the Generosity of Others: Declined HCV-NAT Offers Subsequently Transplanted Have Excellent Outcomes

R. Gilroy, S. Sell, J. Krong, A. Gagnon, I. Zendejas, S. Fujita, M. Rodriguez, D. Alonso

Transplant Services, Intermountain Healthcare, Murray, UT

Meeting: 2020 American Transplant Congress

Abstract number: D-117

Keywords: Allocation, Donors, marginal, Hepatitis C, Outcome

Session Information

Session Name: Poster Session D: Liver: MELD, Allocation and Donor Issues (DCD/ECD)

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: There is variability between programs in the acceptance of organ offers. This paper examines offer, acceptance and program performance with HCV NAT positive donor offers.

*Methods: In a 3 year period, between 9/1/2016 and 9/1/2019, HCV-NAT positive to HCV-NAT negative recipients occurred. On these patients all donor, recipient and procurement data was analyzed.

*Results: Recipients: The most common indications were non-alcoholic steatohepatitis (7/22), primary sclerosing cholangitis (6/22) & alcohol (4/22) with 3/22 having concurrent hepatocellular carcinoma & 1/22 cholangiocarcinoma. Recipients were male (63.6%), median age 49 yrs (IQR 35.7-63), blood group O (50%), median laboratory MELD 24 (14-35) and median allocation MELD 25.2 (17-40). One simultaneous liver & kidney transplant occurred. Donors: 8/22 (81.8%) were male, median donor age 32.5 (IQR: 24-36.2) and median BMI 25.6 (IQR 21.8-27.4) kg/m2. The common causes of death were Anoxia – Drug intoxication (16/22) 72.7% & head trauma (3/22) 13.6%. 20/22 (90.9%) had IV drug use while 2/22 D+ not categorized as PHS increased risk. Liver biopsies at donation had some degree of inflammation with macrovesicular steatosis ≥5% present in 6/22 with 2/22 having ≥25%. 7/22 donors had fibrosis with 3/22 stage 2 and none >2. The most common genotypes were 1 (11/22) 50%, & 3A (7/22) 31.8%. Allocation: The sequence for offers was 41.3 with 3/22 sequence 1, 9/22 at a sequence < 10 with 10/22 a sequence > 10; the highest sequence 338. Most procurements (59%) were national offers, with 5 (38.4%) from UNOS region 10. The median distance traveled was 1002 nautical miles (IQR: 511-1266), median flight time 158.5 min (IQR: 85.75-180), median cold ischemia time 445 min (IQR: 347.5-565), & median warm ischemia time of 35.5 min. Outcomes: Both patient and graft-survival were 95.4% with median follow up 576 days. Average length of stay was 10.2 days (range 5-37). The isolated post-transplant death was a ruptured hepatic artery on day 38 in a recipient transplanted for cholangiocarcinoma. HCV treatment was commenced within 90 days and all treated patients attained SVR 12. 5 patients had biopsies for abnormal liver enzymes with 3 having changes consistent with acute rejection, 2 of which were treated while one had a hepatitis in the absence of HCV and distant to the HCV SVR. Protocol biopsies were performed in all but one recipient (14/15) at 1 year with only one showing fibrosis from a steatohepatitis and possible alloimmune hepatitis.

*Conclusions: HCV offers are most often national offers and refused by more than one program before being transplanted at ours. Clinical outcomes for recipients of these previously declined offers are excellent and pre-transplant fibrosis appears to reverse.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Gilroy R, Sell S, Krong J, Gagnon A, Zendejas I, Fujita S, Rodriguez M, Alonso D. Lowering Meld, Diminishing Length of Stay, and Increasing Liver Transplant Numbers Comes Through the Generosity of Others: Declined HCV-NAT Offers Subsequently Transplanted Have Excellent Outcomes [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/lowering-meld-diminishing-length-of-stay-and-increasing-liver-transplant-numbers-comes-through-the-generosity-of-others-declined-hcv-nat-offers-subsequently-transplanted-have-excellent-outcomes/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences